Discover our partners
If you are interested in learning more about the research and development pipeline of Endoceutics and the opportunities for licensing, please contact Endoceutics directly.
AMAG Pharmaceuticals is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives.
On February 14, 2017, AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) and Endoceutics, Inc. announced that they entered into an exclusive license agreement that provides AMAG with U.S. commercial rights to Intrarosa (prasterone). Intrarosa is the only FDA-approved, locally administered, daily, non-estrogen product for the treatment of moderate-to-severe dyspareunia (pain during intercourse), a common symptom of vulvar and vaginal atrophy (VVA), due to menopause. Unlike conventional pharmacological estrogen-containing medications, Intrarosa™ does not carry a boxed safety warning in its label.
Headquartered in Waltham, Massachusetts, AMAG works to develop and deliver important therapeutics, conduct clinical research in areas of unmet need, and create education and support programs for the patients and families they serve.
In addition to Intrarosa, AMAG’s products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR, AMAG helps families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.
In 1979, Dr. Labrie and his team discovered that chronic administration of GnRH agonists in men induced medical castration. The therapeutic administration of GnRH agonists creates an effect equivalent to surgical castration but is far more acceptable to patients, thus permitting generalized use, especially in localized prostate cancer where long-term treatment is needed. In 1985, Schering-Plough and Dr. Fernand Labrie signed an agreement for the commercialization of the Combination of GnRH agonists or surgical castration with the antiandrogen flutamide. The combination of GnRH agonists and flutamide, also called combined androgen blockade, became the first treatment demonstrated to prolong life in prostate cancer and is now the standard treatment worldwide. Moreover, the data first obtained by Dr. Labrie's team have shown that more than 90% of localized prostate cancers can be cured by combined androgen blockade.
In 1992, EndoResearch signed a collaborative agreement with Schering-Plough for the development of acolbifene against breast cancer.
Schering-Plough Corporation was a United States-based pharmaceutical company. It was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG in Germany. In 1971, the Schering Corporation merged with Plough to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough, with the new company taking the name of Merck & Co.